The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 01, 2021

Filed:

Dec. 13, 2018
Applicant:

Adaptive Biotechnologies Corporation, Seattle, WA (US);

Inventors:

Malek Faham, Pacifica, CA (US);

Thomas Willis, San Francisco, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); C12Q 1/6827 (2018.01); C12Q 1/6809 (2018.01); C12N 15/10 (2006.01); C12Q 1/6881 (2018.01); C12Q 1/6883 (2018.01); C12Q 1/6869 (2018.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); C12N 15/1072 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/6881 (2013.01); C12Q 1/6883 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); Y02A 90/10 (2018.01);
Abstract

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.


Find Patent Forward Citations

Loading…